Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 8, 2014, Pages 2137-2147

  Crowther, Grace S ^a   Chilton, Caroline H ^a   Todhunter, Sharie L ^a   Nicholson, Scott ^a   Freeman, Jane ^b   Baines, Simon D ^c   Wilcox, Mark H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Recurrence; Sessile; Spores

Indexed keywords

CLINDAMYCIN; CYTOTOXIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; BIOFILM; CHEMOSTAT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; EMULSION; FECES COMPOSITION; HUMAN; INTESTINE FLORA; MICROBIAL COMMUNITY; NORMAL HUMAN; RECURRENT INFECTION; SESSILE SPECIES; BACTERIAL SPORE; DRUG EFFECTS; FECES; GROWTH, DEVELOPMENT AND AGING; INTESTINE; MICROBIOLOGY; MICROFLORA; PEPTOCLOSTRIDIUM DIFFICILE; PLANKTON;

ANTI-BACTERIAL AGENTS; BIOFILMS; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; FECES; INTESTINES; MICROBIOTA; PLANKTON; SPORES, BACTERIAL; VANCOMYCIN;

EID: 84904565454     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku116     Document Type: Article

References (46)

1. Wiegand PN, Nathwani D, Wilcox MH et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14.
2. Barbut F, Richard A, Hamadi K et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2386-8.
3. Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 Suppl 2: S93-103.
4. Fekety R, Silva J, Kauffman C et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86: 15-9.
5. Johnson S, Homann SR, Bettin KM et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117: 297-302.
6. Zoetendal EG, von Wright A, Vilpponen-Salmela T et al. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002; 68: 3401-7.
7. Edmiston CE Jr, Avant GR,Wilson FA. Anaerobic bacterial populations on normal and diseased human biopsy tissue obtained at colonoscopy. Appl Environ Microbiol 1982; 43: 1173-81.
8. Croucher SC, Houston AP, Bayliss CE et al. Bacterial populations associated with different regions of the human colon wall. Appl Environ Microbiol 1983; 45: 1025-33.
9. Ceri H, Olson ME, Stremick C et al. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-6.
10. Gomez-Trevino M, Boureau H, Karjalainen T et al. Clostridium difficile adherence to mucus: results of an in vivo and ex vivo assay. Microb Ecol Health D 1996; 9: 329-34.
11. Karjalainen T, Barc MC, Collignon A et al. Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus. Infect Immun 1994; 62: 4347-55.
12. Lawley TD, Clare S,Walker AWet al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 2009; 77: 3661-9.
13. Dawson LF, Valiente E, Faulds-Pain A et al. Characterisation of Clostridium difficile biofilm formation, a role for Spo0A. PLoS One 2012; 7: e50527.
14. Donelli G, Vuotto C, Cardines R et al. Biofilm-growing intestinal anaerobic bacteria. FEMS Immunol Med Microb 2012; 65: 318-25.
15. Ethapa T, Leuzzi R, Ng YK et al. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol 2013; 195: 545-55.
16. Crowther GS, Chilton CH, Todhunter SL et al. Development and validation of a chemostat gut model to study both planktonic and biofilm modes of growth of Clostridium difficile and human microbiota. PLoS One 2014; 9: e88396.
17. Baines SD, O'Connor R, Saxton K et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2009; 63: 520-5.
18. Baines SD, O'Connor R, Huscroft G et al. Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 2009; 63: 838-9.
19. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
20. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
21. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
22. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012; 18 Suppl 6: 5-12.
23. Ghantoji SS, Sail K, Lairson DR et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74: 309-18.
24. Chilton CH, Freeman J, Crowther GS et al. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2012; 67: 2434-7.
25. Chilton CH, Crowther GS, Freeman J et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 2014; 69: 451-62.
26. Macfarlane S, Woodmansey EJ, Macfarlane GT. Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system. Appl Environ Microbiol 2005; 71: 7483-92.
27. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-8.
28. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
29. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-8.
30. Crowther GS, Baines SD, Todhunter SL et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013; 68: 168-76.
31. Cha JO, Park YK, Lee YS et al. In vitro biofilm formation and bactericidal activities of methicillin-resistant Staphylococcus aureus clones prevalent in Korea. Diagn Microb Infect Disease 2011; 70: 112-8.
32. Furustrand Tafin U, Corvec S, Betrisey B et al. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 2012; 56: 1885-91.
33. Smith K, Perez A, Ramage G et al. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents 2009; 33: 374-8.
34. Vlamakis H, Aguilar C, Losick R et al. Control of cell fate by the formation of an architecturally complex bacterial community. Genes Dev 2008; 22: 945-53.
35. Hamon MA, Lazazzera BA. The sporulation transcription factor Spo0A is required for biofilm development in Bacillus subtilis. Mol Microb 2001; 42: 1199-209.
36. Veening JW, Kuipers OP, Brul S et al. Effects of phosphorelay perturbations on architecture, sporulation, and spore resistance in biofilms of Bacillus subtilis. J Bacteriol 2006; 188: 3099-109.
37. Deakin LJ, Clare S, Fagan RP et al. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 2012; 80: 2704-11.
38. Ghosh S, Zhang P, Li YQ et al. Superdormant spores of Bacillus species have elevatedwet-heat resistance and temperature requirements for heat activation. J Bacteriol 2009; 191: 5584-91.
39. Ghosh S, Scotland M, Setlow P. Levels of germination proteins in dormant and superdormant spores of Bacillus subtilis. J Bacteriol 2012; 194: 2221-7.
40. Wei J, Shah IM, Ghosh S et al. Superdormant spores of Bacillus species germinate normally with high pressure, peptidoglycan fragments, and bryostatin. J Bacteriol 2010; 192: 1455-8.
41. Nerandzic MM, Donskey CJ. Triggering germination represents a novel strategy to enhance killing of Clostridium difficile spores. PLoS One 2010; 5: e12285.
42. Darouiche RO, Dhir A, Miller AJ et al. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. J Infect Dis 1994; 170: 720-3.
43. Cargill JS, Upton M. Low concentrations of vancomycin stimulate biofilm formation in some clinical isolates of Staphylococcus epidermidis. J Clin Pathol 2009; 62: 1112-6.
44. Rice SA, Koh KS, Queck SY et al. Biofilm formation and sloughing in Serratia marcescens are controlled by quorum sensing and nutrient cues. J Bacteriol 2005; 187: 3477-85.
45. Lee SF, Li YH, Bowden GH. Detachment of Streptococcus mutans biofilm cells by an endogenous enzymatic activity. Infect Immun 1996; 64: 1035-8.
46. Gjermansen M, Ragas P, Sternberg C et al. Characterization of starvation-induced dispersion in Pseudomonas putida biofilms. Environ Microbiol 2005; 7: 894-906.